Chris van Ingen, the head of Agilent Technologies’ Life Sciences and Chemical Analysis business unit, told analysts Monday that there is a “resurgence” in DNA analysis based on microarray-based applications for comparative genomic hybridization and location analysis.

Microarray analysis of RNA is the larger part of the microarray market, where Agilent is considered the No. 2 player after dominant Affymetrix. It’s a market that is regarded as nearing maturity, with sales growth leveling off as whole-genome microarrays move toward near-commodity status.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.